🇺🇸 FDA
Patent

US 12186375

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

granted A61KA61K38/37A61K47/60

Quick answer

US patent 12186375 (Factor VIII chimeric and hybrid polypeptides, and methods of use thereof) held by BIOVERATIV THERAPEUTICS INC. expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/37, A61K47/60, A61K47/68, A61P